Skip to main content

Table 1 Baseline characteristics for the main study cohort and sub-populations by cancer survivor (> = 1 year) status

From: Statin use in cancer survivors versus the general population: cohort study using primary care data from the UK clinical practice research datalink

  Main Study Cohorta High Cardiovascular Risk Cohortb Statin Initiator Cohortc
Cancer Survivor Control Cancer Survivor Control Cancer Survivor Control
n = 131,676 n = 3,324,152 n = 4202 n = 113,035 n = 12,142 n = 366,280
n (%) n (%) n (%) n (%) n (%) n (%)
Sex
 Male 58,587 (44.7) 1,618,820 (48.70) 2659 (63.3) 80,264 (71.0) 5959 (49.1) 194,430 (53.1)
 Female 72,823 (55.3) 1,705,299 (51.30) 1543 (36.7) 32,771 (29.0) 6183 (50.9) 171,848 (46.9)
Age (years)
 Median (IQR) 66.5 (57.5–75.5) 50.5 (42.1–62.3) 69.1 (64.2–72.9) 64.2 (58.4–69.8) 68.9 (62.4–75.1) 62.6 (54.9–70.2)
 40–49 14,117 (10.7) 1,529,272 (46.0) 27 (0.6) 5410 (4.8) 351 (2.9) 45,132 (12.3)
 50–59 24,564 (18.6) 775,972 (23.3) 368 (8.8) 27,121 (24.0) 1630 (13.4) 96,664 (26.7)
 60–69 38,078 (28.9) 521,777 (15.7) 1815 (43.2) 50,847 (45.0) 4393 (36.2) 125,540 (34.3)
 70–79 33,983 (25.8) 303,231 (9.1) 1765 (42.0) 26,713 (23.6) 4086 (33.7) 73,598 (20.1)
 80+ 20,934 (15.9) 193,900 (5.8) 227 (5.4) 2944 (2.6) 1682 (13.7) 25,346 (6.9)
BMI (kg/m2)
 Mean (SD) 26.9 (5.3) 26.9 (5.3) 28.3 (4.8) 27.8 (5.1) 28.2 (5.4) 28.7 (5.6)
  < 18.5 2748 (2.1) 48,109 (1.4) 50 (1.2) 897 (0.8) 131 (1.1) 2906 (0.8)
 18.5–25 46,037 (35.0) 1,130,838 (34.0) 1127 (26.8) 27,294 (24.2) 3175 (26.9) 86,962 (24.5)
  ≥ 25 74,375 (56.5) 1,736,648 (52.2) 2925 (69.6) 81,734 (72.3) 8504 (72.0) 265,128 (74.7)
 Missing 8516 (6.5) 408,557 (12.3) 100 (2.4) 3113 (2.8) 332 (2.7) 11,285 (3.1)
Cholesterol (mmol/L)
 Mean (SD) 5.3 (1.2) 5.4 (1.1) 5.7 (1.0) 5.8 (1.1) 6.0 (1.3) 6.1 (1.3)
 Normal (< 5) 42,503 (32.3) 796,230 (23.9) 898 (21.4) 21,543 (19.1) 2242 (18.7) 58,780 (16.2)
 Mod (5–8) 62,529 (47.5) 1,405,997 (42.3) 3137 (74.6) 85,221 (75.4) 8965 (74.8) 278,848 (76.9)
 High (> 8) 1704 (1.5) 38,297 (1.2) 92 (2.2) 3316 (2.9) 775 (6.47) 25,032 (6.9)
 Missing 24,940 (18.9) 1,083,578 (32.6) 75 (1.8) 2955 (2.6) 157 (1.29) 3640 (1.0)
Smoking status
 Never 46,606 (35.4) 1,358,706 (40.9) 1194 (28.4) 29,306 (25.9) 3729 (30.7) 118,728 (32.4)
 Ex 61,969 (47.1) 965,510 (29.1) 2133 (50.8) 46,494 (41.2) 6572 (54.1) 166,482 (45.5)
 Current 22,627 (17.2) 885,915 (26.6) 875 (20.8) 37,190 (32.9) 1840 (15.2) 80,841 (22.1)
 Missing 474 (0.4) 114,021 (3.4) < 5 45 (0.0) < 5 299 (0.1)
Alcohol status (non- ex- current drinker)
 Non 25,030 (19.0) 577,211 (17.4) 742 (17.7) 18,139 (16.1) 2500 (27.3) 75,516 (27.5)
 Ex 3778 (2.84) 74,249 (2.2) 162 (3.9) 4079 (3.6) 447 (4.9) 13,002 (4.7)
 Current
  light 48,354 (36.7) 1,042,681 (31.3) 1629 (38.8) 40,996 (36.3) 4868 (53.1) 140,039 (51.0)
  moderate 4776 (3.6) 106,934 (3.2) 224 (5.3) 5904 (5.2) 503 (5.5) 15,837 (5.8)
  heavy 5025 (3.8) 150,372 (4.5) 254 (6.0) 9229 (8.2) 562 (6.1) 19,668 (7.2)
  unknown 2819 (2.1) 74,769 (2.3) 117 (2.8) 4193 (3.7) 280 (3.1) 10,747 (3.9)
 Missing 41,894 (31.8) 1,297,936 (39.0) 1074 (25.6) 30,495 (27.0) 2982 (24.6) 91,474 (25.0)
Medical history
 Diabetes 12,045 (9.2) 153,405 (4.6) 187 (4.5) 5308 (4.7) 2239 (18.4) 69,156 (18.9)
 CKD 9577 (7.3) 28,419 (0.9) 368 (8.8) 5465 (4.8) 1450 (12.0) 24,464 (6.7)
 Chronic liver disease 2223 (1.7) 39,429 (1.2) 75 (1.8) 7975 (1.8) 221 (1.8) 6378 (1.7)
Index of Multiple Deprivation quintile
 1 (least) 16,993 (12.9) 298,566 (9.0) 641 (15.2) 12,842 (11.4) 1697 (11.1) 40,458 (11.1)
  2 12,043 (12.9) 340,205 (10.2) 588 (14.0) 13,616 (12.6) 1607 (13.2) 43,074 (11.8)
  3 18,708 (14.2) 384,484 (11.6) 545 (13.0) 14,211 (12.6) 1655 (13.6) 48,491 (13.2)
  4 64,007 (48.6) 1,978,653 (59.5) 1894 (45.1) 57,464 (50.8) 5615 (46.2) 188,142 (51.4)
 5 (most) 14,985 (11.4) 322,244 (9.7) 434,534 (12.7) 14,902 (13.2) 1586 (13.1) 46,115 (12.6)
Calendar year
 2005–07 62,916 (47.8) 2,423,116 (72.9) 623 (14.8) 23,020 (20.4) 4105 (33.8) 156,589 (42.8)
 2008–10 34,416 (26.1) 471,289 (14.2) 1681 (40.0) 48,349 (42.8) 4310 (35.5) 124,339 (33.9)
 2011–13 34,344 (26.1) 429,747 (12.9) 1898 (45.2) 41,666 (36.9) 3727 (30.7) 85,352 (23.3)
  1. aCovariates were measured at baseline (or closest recording) defined in the ‘main study cohort’ as the date of the start of unexposed (non-cancer) and exposed (≥ 1 year post cancer diagnosis) follow-up time. Patients in the Main Study Cohort could contribute person-time to exposed and unexposed cohorts
  2. bBaseline was defined in the ‘high cardiovascular risk cohort’ as the date of the first high cardiovascular risk score. Patients could only be included in one of the comparison cohorts
  3. cBaseline was defined in the ‘statin initiator cohort’ as the date of the first statin prescription. Patients could only be included one of the comparison cohorts. If a non-cancer patient developed cancer while on statin therapy they were censored